dipeptidyl peptidase


Also found in: Wikipedia.

di·pep·ti·dyl pep·ti·dase

(dī-pep'ti-dil pep'ti-dās),
A hydrolase occurring in a number of forms: dipeptidyl peptidase I, dipeptidyl transferase, cleaving dipeptides from the amino end of polypeptides; dipeptidyl peptidase II, with properties similar to those of I, has a different specificity and acts preferably on tripeptides; dipeptidyl peptidase III acts on longer peptides.

di·pep·ti·dyl pep·ti·dase

(dī-pep'ti-dil pep'ti-dās)
A hydrolase occurring in two forms: dipeptidyl peptidase I, dipeptidyl transferase, cleaving dipeptides from the amino end of polypeptides; dipeptidyl peptidase II, with properties similar to those of form I, has a different specificity.
References in periodicals archive ?
Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC.
However, the available data on the inhibition of dipeptidyl peptidase in RA suggest that we should be careful in terms of the use of DPP-4 inhibitors in the treatment of diabetic patients with RA.
High and growing diabetes population in the country, rising obese and geriatric population, and rapid market adoption of drugs from the classes such as Dipeptidyl Peptidase 4 (DPP-4) inhibitors, Glucagon-Like Peptide (GLP)-1, Sodium-Glucose Transport Proteins (SGLT-1) and others would drive the anti-diabetes market in the forecast period.
Inhibition of dipeptidyl peptidase IV (DPP-IV) is one of the mechanisms explaining the hypoglycemic effect of berberine.
In the recently completed 12 week Phase IIb clinical trial in 494 patients with type 2 diabetes mellitus (T2DM), 'Melogliptin', Glenmark's investigational medicine from a new class of diabetes treatments called dipeptidyl peptidase 4 (DPP-4) inhibitors, improved glycemic control in patients with type 2 diabetes mellitus and exhibited excellent safety and tolerability profile.
These nine articles describe some of the work being done to differentiate markers and use their presence to detect and treat a range of cancers, addressing the characterization of breast cancer subtypes in a large retrospective study, intraocular lymphoma markers, polymorphisms in genes associated with certain T-cell lymphomas, tumor antigens that are markers of minimal residual disease in acute myeloid leukemia, thyroid tumor markers, activity and expression of dipeptidyl peptidase IV and cathepsin H in human cutaneous melanoma compared to other common cancers, melanoma inhibitory activity as a serological marker in metastic melanoma, and the promise (or myth) of the tumor necrosis factor alpha receptors p55 and p75 in ovarian cancer detection.
Both compounds inhibit an enzyme called dipeptidyl peptidase 4 (DPP-4), which usually controls the body's production of a hormone, called GLP1.
Tokyo, Japan, June 15, 2006 - (JCN) - Ono Pharmaceutical and Banyu Pharmaceutical have obtained positive results in the recent clinical trials of sitagliptin, a dipeptidyl peptidase IV (DPP4) inhibitor.
OSI) Prosidion's lead compound, PSN9301, is a Dipeptidyl Peptidase IV (DPIV) inhibitor currently in Phase II clinical trials.
The rights to the dipeptidyl peptidase IV inhibitors had earlier been shared between PPD and Syrrx Inc.
13) GLPs are broken down by dipeptidyl peptidase IV (DPP-IV), and inhibitors of this enzyme have also shown promise in early clinical trials.
The Company has pioneered the field of dipeptidyl peptidase 4 (DP4)-inhibition for the treatment of type 2 diabetes.